Axol Bioscience, in partnership with StrataStem, has announced the release of a collection of induced pluripotent stem cell (iPSC) lines derived from patients with sporadic Alzheimer’s Disease (sAD).  

This ‘Sporadic Alzheimer’s Disease iPSC Line Collection’ is available for use in Axol’s custom iPSC-derived cell manufacturing program and represents a significant advancement in the tools available for pre-clinical in vitro model building and drug discovery research.

The collection features 20 fully characterized iPSC lines, including both sAD patients and healthy donor controls, all obtained with full ethical and commercial consent from donors in the Greater Manchester area of the UK. These cell lines are particularly valuable for researchers as they represent age-relevant, gender-mixed samples with comprehensive documentation of ApoE genotypes, medical histories, and family histories. 

“This collection addresses a critical gap in Alzheimer’s disease research by providing high-quality iPSCs from sporadic AD patients that can be used in multi-cell type manufacturing,” said Duncan Borthwick, Head of Sales and Marketing at Axol Bioscience. “These cells enable the development of complex sAD in vitro models that will engage in the complexity of the Alzheimer’s condition.” 

Key Features of the Collection: 

• Custom manufacturing capabilities for multiple neural cell types, including cortical excitatory neurons, cortical inhibitory neurons, microglia, and astrocytes 

• Complete ApoE genotype profiling, including representation of E2/E3, E3/E3, E3/E4, and E4/E4 variants 

• Rigorous donor screening and selection criteria and quality control of manufactured cells 

• Flexible delivery options, including direct shipment to clients or third-party service providers 

• Scalable and customizable manufacturing processes 

The cell lines are immediately available for custom manufacturing projects and can be utilized in various research applications, from basic disease modeling to advanced drug discovery programs. Researchers can access these cells through direct purchase or as part of Axol’s comprehensive service offerings. 

For more information about the sAD iPSC collection or to discuss custom manufacturing opportunities, interested parties can contact operations@axolbio.com. 

About Axol Bioscience

Axol Bioscience brings over a decade of experience in iPSC technology, specializing in the manufacturing of high-quality, functional iPSC-derived cells. The company offers a range of services including disease model creation, compound screening, assay development, reprogramming, and gene editing. 

About StrataStem

StrataStem specializes in identifying, collecting, and processing tissues from patients with neurological diseases. The company provides comprehensive patient and clinical history documentation, including genotyping for disease-associated variants, to support the development of disease models suitable for various research applications. 

Learn more in this new guide: